Patient safety in pathway to biosimilars

In a recent article at the Statesman Journal, John Horton, President of LegitScript in Portland, is the former Associate Deputy Director at the US Office of National Drug Control Policy, shares his opinions on the state of biosimilars and what should come first in the minds of the FDA who is approving these drugs for use.

Some of the things to take into consideration about the safety and cost savings of the drug according to Horton are:

• - This form of drug is just 20-25% cheaper due to the manufacturing process
• - Names of the biologic and biosimilar should be very different in order to differentiate between the two drugs for the consumers
• -Patient safety should be number one - just because the form of the medicine is cheaper, it doesn't mean that it's still cheaper if it doesn't have the same result in terms of treatment

This fall at the Business of Biosimilars and Biobetters, experts will gather for the Compliant Market to Consumer Acceptance which will look at the best practices for naming and labeling biosimilars. For more information, download the brochure here.

Share this article with your social network, just click below to share now!

Share |